SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010 and is headquartered in Novato, CA.

Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc

FDA approval of UX111, a gene therapy for Sanfilippo syndrome type A, is driving attention, with traders highlighting the first approved treatment for the disease and a potential priority-review voucher. The community is broadly bullish but debating the muted share-price reaction, commercialization constraints, cost-cutting needs, and whether short covering or additional company news will be required for further momentum.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeaves proposed convertible-note financing and ATM share-sale program have driven attention, with traders focused on added leverage, potential dilution, and managements timing as the stock fell despite broader AI strength. Some bulls argue the capital will fund expansion backed by strong compute demand and new higher-priced contracts, but near-term sentiment is dominated by financing concerns.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

A Ninth Circuit ruling that sports-event contracts are bets rather than federally protected swaps is drawing attention as a potential regulatory win for DraftKings, weakening Kalshi and other prediction-market competitors and strengthening traditional sportsbook protections. Traders remain divided, with bulls citing the ruling and NFL-season demand while skeptics point to possible Supreme Court review, continued competition, and DraftKings own exposure to prediction markets.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

A sharp semiconductor and AI-led rebound, reinforced by bullish options flow and short-squeeze speculation, has driven attention to AMD. Traders remain divided between expectations of continued momentum from strong AI-chip demand and concerns that the move is overextended, richly valued, and vulnerable to a pullback amid further rate hikes.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

A sharp, high-volume move without a confirmed company-specific announcement has traders focused on a technical breakout, possible short covering, and speculation around upcoming Anktiva catalysts such as papillary bladder-cancer review and lymphopenia data. Debate remains whether the rally reflects institutional or broader biotech buying and Nant/PDSB developments, or a recurring momentum-driven move vulnerable to a pullback.

Generac Holdings, Inc. engages in the business of designing and manufacturing energy technology solutions. It operates under the Domestic and International segments. The Domestic segment includes the legacy Generac business and the acquisitions that are based in the United States and Canada. The International segment focuses on Generac business' Latin American export operations. The company was founded in 1959 and is headquartered in Waukesha, WI.

Generac Holdings Inc

Generac is drawing attention after signing a long-term agreement to supply Amazon with backup generators for data centers, reinforcing its positioning as an AI-infrastructure power supplier. Traders are broadly bullish on the added revenue visibility and potential for further hyperscaler orders, while others are focused on profit-taking, warrant-related dilution, and the fact that the deals maximum value is not fully committed.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Exploratory reports that SK Hynix may use Intels planned Ohio facility for U.S. memory production, potentially through a lease or joint venture, are driving attention and bullish positioning. Traders view the talks as a foundry and AI-memory catalyst, while skeptics note that SK Hynix has said no agreement has been finalized and warn the move could fade.

Schrödinger, Inc. engages in the provision of chemical simulation software solutions to pharmaceutical industry. It operates through the Software and Drug Discovery business segments. The Software segment sells software to transform drug discovery across the life sciences industry and to customers in materials science industries. The Drug Discovery segment offers diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The company was founded by Richard A. Friesner, William A. Goddard, III and Murco Ringnalda in 1990 and is headquartered in New York, NY.

Schrodinger Inc

A well-received investor presentation and optimism around Schrodingers AI-powered drug-discovery platform and growing Big Pharma interest are driving the sharp move. Traders are split between viewing it as a durable re-rating and warning that the stock is overbought, with some speculating about future partnerships or a buyout without confirmation.

Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Cleveland, OH.

Abeona Therapeutics Inc

Abeonas slower-than-expected ZEVASKYN commercial ramp and manufacturing issue that left one treatment non-billable are driving attention after the latest quarterly update, alongside continued concern about treatment-center activation, cash burn, and management guidance. Traders remain divided: bears question demand, execution, and dilution risk, while bulls view the setback as temporary and focus on expanding treatment centers and potential upside from partner Ultragenyxs UX111 FDA decision.

T-Mobile US, Inc. engages in the provision of wireless communications services under the T-Mobile and MetroPCS brands. It offers postpaid and prepaid wireless voice, messaging and data services, and wholesale wireless services. The company was founded in 1994 and is headquartered in Bellevue, WA.

T-Mobile US Inc

A post-earnings selloff is driving attention after T-Mobile delivered stronger profit but slightly missed revenue expectations and signaled slower account growth, prompting debate over whether the decline is an overreaction. Bulls view the shares as oversold and a buying opportunity, while bears cite valuation, debt, intensifying wireless competition and the potential threat from Starlink.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

What's Going On With CNS Pharmaceuticals Stock On Wednesday?

CNS Pharmaceuticals plans a pivot to an acquisition-led strategy, capital raise, and technicals signal momentum with caution.read more...

Best Small Cap Stocks To Keep An Eye On - May 4th

Direxion Daily MU Bull 2X Shares, Inflection Point Acquisition Corp. II, CNS Pharmaceuticals, Critical Metals, Elong Power, Direxion Daily PLTR Bear 1X Shares, and Spring Valley Acquisition are the seven Small Cap stocks to watch today, according to MarketBeat's stock screener tool. Small-cap stock...

Medical Stocks To Watch Today - May 4th

Arcellx, Eli Lilly and Company, UnitedHealth Group, CNS Pharmaceuticals, and Johnson & Johnson are the five Medical stocks to watch today, according to MarketBeat's stock screener tool. Medical stocks are shares of publicly traded companies involved in healthcare including pharmaceuticals, biotec...

Pharmaceutical Stocks To Follow Today - May 4th

Eli Lilly and Company, CNS Pharmaceuticals, Novo Nordisk A/S, Abbott Laboratories, and Pfizer are the five Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of publicly traded companies that research, develop, manufacture, and sell...

Institutional Giants Are Piling into Four of These NASDAQ Plays

The market is currently seeing a flurry of activity as companies across the biotech and technology sectors secure substantial funding and execute strategic transformations. $CNSP, $KBLB, $PN, $RLYB, $ADVB, $CLNN, $CABA

Why Did CNSP Stock Surge 330% Today?

Equity

The company announced a private placement, involving the sale of 650,000 common shares at $2.30 each, along with pre-funded warrants tied to over 9.1 million shares.

Nano-Cap CNS Pharmaceuticals Stock Explodes As Capital Raise Fuels Pivot

CNS Pharmaceuticals announces $22.5 million financing as the company pivots its strategy, eyes asset acquisitions.read more...

CNS Pharmaceuticals Secures $22.5 M in Oversubscribed Private Placement

CNS Pharmaceuticals (NASDAQ:CNSP) significantly boosted its capital reserves, entering into securities purchase agreements for a private placement expected to generate $22.5 million in gross proceeds.

CNS Pharmaceuticals Stock Declines On Wider Q1 Loss: But Retail Stays Unmoved

The company intends to commence the phase 2 study of its lead program, TPI 287, to treat Glioblastoma Multiforme (GBM) by year-end.

This account has been verified as an official CNSP representative.

Verified Account

CNS Pharma

CNS Pharmaceuticals, Inc. is a preclinical stage pharmaceutical company, which engages in the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. Its product pipeline includes berubicin, and CNS-12. The company was founded by Waldemar Priebe in July 2017 and is headquartered in Houston, TX.

Cns Pharmaceuticals Inc

Bearish Sentiment

No more this year

One more

Two more

The Federal Reserve raised interest rates by a quarter point to a range of 3.75%-4.00% on Wednesday, its first hike since July 2023, but Fed Chair Kevin Warsh signaled the tightening cycle isn't over. How many more rate hikes do you expect by the end of 2026? Vote and explain your reasoning in the comments.

The Fed hiked rates 25bps yesterday, its first since 2023, but signaled it&#39;s not done - projections point to one or two more hikes this year. How many total hikes do you expect by year-end?

Stocktwits

The Fed hiked rates 25bps yesterday, its first since 2023, but signaled it's not done - projections point to one or two more hikes this year. How many total hikes do you expect by year-end?

Feed

News

Sentiment

Fundamentals

Info

CNSP Cns Pharmaceuticals Inc

Fundamentals

Latest CNSP News